Now that the Securities and Exchange Commission has made public its plans to re-evaluate the current rules establishing investor access to private investments such as hedge funds, we should expect the familiar battle lines to start re-emerging.
As my colleague Mark Schoeff Jr. reported on Tuesday, Securities and Exchange Commission Chairman Mary Jo White is considering changes to the criteria that must be met to be considered an accredited investor, which likely would expand the market of potential participants in the market.
Currently, only investors who have a net worth of $1 million, excluding the value of their homes, or an income greater than $200,000 can buy unregistered securities or invest in private-equity and hedge funds.
Top Telecom Stocks To Invest In Right Now: Amerco (UHAL)
AMERCO, through its subsidiary U-Haul International, Inc., a do-it-yourself moving and storage operator that supplies products and services to help people move and store their household and commercial goods in the United States and Canada. The company engages in the rental of trucks, trailers, specialty rental items, and self-storage spaces primarily to the household mover as well as sales of moving supplies, towing accessories and propane. It also offers eMove, an online marketplace, which connects consumers to independent moving help service providers and independent self-storage affiliates, as well as manages self-storage properties. In addition, the company provides loss adjusting and claims handling services, as well as underwrites moving and storage protection packages, including Safemove and Safetow that provide moving and towing customers with a damage waiver, cargo protection, and medical and life insurance coverage; Safestor, which protects storage customers from loss on their goods in storage; and Super Safemove that offer rental customer with a layer of primary liability protection. Further, it provides life and health insurance products primarily to the senior market through the direct writing or reinsuring of life insurance, medicare supplement, and annuity policies. The company rents its orange and white U-Haul trucks and trailers, as well as offers self-storage rooms through a network of approximately 1,400 company operated retail moving centers and approximately 15,000 independent U-Haul dealers. Its rental fleet consists of approximately 101,000 trucks, 82,000 trailers, and 33,000 towing devices, as well as operates approximately 1,115 self-storage locations in North America, with approximately 411,000 rentable rooms. The company was founded in 1945 and is based in Reno, Nevada.
Advisors' Opinion:- [By Rich Smith]
Given my druthers, were I asked to recommend a truck rental shop today, I think I'd have to go with U-Haul owner AMERCO (NASDAQ: UHAL ) instead. It's got the free cash flow that Ryder lacks, plus a cheaper P/E, a slightly faster growth rate, and a smaller debt load. Honestly, I don't "love" AMERCO either -- but it's a heck of a better value than Ryder.
Top 10 Income Stocks To Own Right Now: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By George Budwell]
Inovio Pharmaceuticals (NYSEMKT: INO ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.
- [By Sean Williams]
On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Inovio Pharmaceuticals (NYSEMKT: INO ) both put investors in their happy place.
Top 10 Income Stocks To Own Right Now: IN Media Corp (IMDC)
IN Media Corporation, formerly Tres Estrellas Enterprises, Inc., incorporated on March 5, 2007, is a development-stage company. The Company focuses on providing integrated Internet protocol television (IPTV) services for platform providers for any device from large screen televisions to handheld mobile phones. It provides a combination of hardware, software, manufacturing and content services for platform providers to either complete their offerings or provide an all-in-one solution. On October 16, 2009, the Company executed an agreement between In-Media Corporation (In-Media) and the Company, subsequent to which In-Media was merged into the Company.
The Company�� partnerships with platform providers, such as Comcast, AT&T, DirecTV, provide an installed base of customers, as well as allowing platform providers to be the billing and service interface to customers. The Company is focusing on its first implementation in China through its Chinese distributor, which will include provision of set top boxes (STB)-related system support, reference platforms and technology, and access to over 4,000 titles of Hollywood and Bollywood movies.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks IN Media Corp (OTCMKTS: IMDC), Epazz Inc (OTCMKTS: EPAZ) and Polaris International Holdings (OTCMKTS: PIHN) have been busy developing new devices/products or making acquisitions. Moreover, at least two of these small cap stocks have been the subject of paid promotions or investor relations types of activities. Keeping that in mind, will new devices/products or acquisitions help these small caps along with their investors or traders? Here is a closer look:
Top 10 Income Stocks To Own Right Now: Total SA (FP)
Total SA is a France-based integrated international oil and gas company. It is an integrated international oil and gas company and a chemicals manufacturer. Total engages in all aspects of the petroleum industry, including Upstream operations (oil exploration and production, together with activities related to natural gas), Refining & Chemicals (refining, petrochemicals, speciality chemicals, crude oil trading and shipping) and Marketing & Services (focused on the supply and sale of petroleum products, together with activities related to renewable energy). In April 12, 2013, it inaugurated the partnership with Veolia Environnement SA the Osilub plant. In July 2013, it sold its TIGF (Transport et Infrastructures Gaz France), gas transport and storage business. In September 2013, it announced the transfer to The National Gas Company of Trinidad &Tobago of all of its E&P assets in Trinidad through the sale of Total E&P Trinidad B.V and Elf Exploration Trinidad B.V. Advisors' Opinion:- [By Sofia Horta e Costa]
Lloyds dropped 3.5 percent after the U.K. government sold a 3.2 billion-pound ($5.1 billion) stake in the lender. Continental and Galp Energia SGPS SA fell at least 2.5 percent as investors sold shares in the companies. Total SA (FP) retreated 1.3 percent following a report that Groupe Bruxelles Lambert SA may dispose of its 4 percent stake in the French oil producer.
Top 10 Income Stocks To Own Right Now: Transcept Pharmaceuticals Inc.(TSPT)
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. Its principal product is the Intermezzo, a low dose sublingual formulation of zolpidem as a sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States. It is also developing TO-2061, a low dose ondansetron adjunctive therapy, which is in Phase II study for patients with obsessive-compulsive disorder. The company was founded in 2002 and is based in Point Richmond, California.
Advisors' Opinion:- [By Roberto Pedone]
An under-$10 biotech stock that's trending very close to triggering a near-term breakout trade is Transcept Pharmaceuticals (TSPT), which is focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. This stock has been hit hard by the bears so far in 2013, with shares off by 36%.
If you take a look at the chart for TSPT, you'll notice that this stock has been trending sideways inside of a big consolidation pattern for the last three months, with shares moving between $2.71 on the downside and $3.25 on the upside. Shares of TSPT are counter-trending higher today in the face of a very weak tape. This move is starting to push the stock within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern.
Traders should now look for long-biased trades in TSPT if it manages to break out above its 50-day moving average at $2.91 a share and then once it takes out more near-term overhead resistance levels at $3.16 to $3.25 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 138,444 shares. If that breakout triggers soon, then TSPT will set up to re-test or possibly take out its next major overhead resistance levels at $4.23 to its 200-day at $4.39 a share. If those levels get taken out with volume, then TSPT could easily hit its next major overhead resistance levels at $5 to $5.50 a share.
Traders can look to buy TSPT off weakness to anticipate that breakout and simply use a stop that sits right below its recent low of $2.71 a share. One can also buy TSPT off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Roberto Pedone]
Transcept Pharmaceuticals (TSPT) is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. This stock closed up 6% to $2.98 in Thursday's trading session.
Thursday's Range: $2.81-$2.99
52-Week Range: $2.77-$6.77
Thursday's Volume: 138,000
Three-Month Average Volume: 158,095From a technical perspective, TSPT spiked sharply higher here right above some near-term support at $2.77 and back above its 50-day moving average at $2.95 with decent upside volume. This move is quickly pushing shares of TSPT within range of triggering a major breakout trade. That trade will hit if TSPT manages to take out some near-term overhead resistance levels at $3.16 to $3.25 with high volume. If that breakout hits, it would also push TSPT outside of a large consolidation pattern the stock has been in for the last three months.
Traders should now look for long-biased trades in TSPT as long as it's trending above some key near-term support at $2.77 and then once it sustains a move or close above those breakout levels with volume that hits near or above 158,095 shares. If that breakout triggers soon, then TSPT will set up to re-test or possibly take out its next major overhead resistance levels at $4.23 to its 200-day moving average at $4.50. Any high-volume move above those levels will then put $4.89 to $5 into range for shares of TSPT.
Top 10 Income Stocks To Own Right Now: World Acceptance Corp (WRLD)
World Acceptance Corporation operates a small-loan consumer finance business in 12 states and Mexico. The Company is engaged in the small-loan consumer finance business, offering short-term small loans, medium-term larger loans, related credit insurance and ancillary products and services to individuals. As of March 31, 2012, the Company offered standardized installment loans through 1,137 offices in South Carolina, Georgia, Texas, Oklahoma, Louisiana, Tennessee, Illinois, Missouri, New Mexico, Kentucky, Alabama, Wisconsin, and Mexico. The Company serves individuals with limited access to consumer credit from banks, credit unions, other consumer finance businesses and credit card lenders. In the United States offices, the Company also offers income tax return preparation services to its customers and others.
During the fiscal year ended March 31, 2012 (fiscal 2012), the Company opened 69 new offices. In each state in which it operates and in Mexico, the Company offers consumer installment loans, which are standardized by amount and maturity. The Company's loans are consumer installment loans, which are payable in fully amortizing monthly installments with terms generally of 4 to 36 months, and all loans are pre-payable at any time without penalty. During fiscal 2012, the Company's average originated gross loan term was approximately 12 months. As of March 31, 2012, the annual percentage rates on loans offered by the Company, which include interest, fees and other charges as calculated for the purposes of the requirements of the federal Truth in Lending Act, ranged from 24% to 204% depending on the loan size, maturity and the state, in which the loan is made. In addition, in certain states, the Company, as agent for an unaffiliated insurance company, sells credit insurance in connection with its loan transactions.
Specific allowable charges vary by state and, consistent with industry practice, the Company generally charges at or close to the maximum rates allowable under app! licable state law in those states that limit loan rates. Statutes in Texas and Oklahoma allow for indexing the maximum loan amounts to the Consumer Price Index. The Company�� loan products are pre-computed loans in which the finance charge is a combination of origination or acquisition fees, account maintenance fees, monthly account handling fee and other charges permitted by the relevant state laws.
The Company, as an agent for an unaffiliated insurance company, markets and sells credit life, credit accident and health, credit property, and unemployment insurance in connection with its loans in selected states where the sale of such insurance is permitted by law. Credit life insurance provides for the payment in full of the borrower's credit obligation to the lender in the event of death. Credit accident and health insurance provides for repayment of loan installments to the lender, which come due during the insured's period of income interruption resulting from disability from illness or injury. Credit property insurance insures payment of the borrower's credit obligation to the lender in the event, which the personal property pledged as security by the borrower is damaged or destroyed by a covered event. Unemployment insurance provides for repayment of loan installments to the lender, which come due during the insured�� period of involuntary unemployment. The Company requires each customer to obtain specific credit insurance in the amount of the loan for all loans originated in Georgia under the Georgia Industrial Loan Act, and encourages customers to obtain credit insurance for all loans originated in South Carolina, Louisiana, Alabama and Kentucky and on a limited basis in Tennessee, Oklahoma, and Texas. Customers in those states obtain such credit insurance through the Company.
In South Carolina, Georgia, Louisiana, Kentucky and Alabama, the Company charges its borrowers for its non-file premiums in connection with certain loans in lieu of recording and perfecting the! Company� �s security interest in the loan collateral. The premiums are remitted to a third party insurance company for non-file insurance coverage. The Company also markets automobile club memberships to its borrowers in Georgia, Tennessee, New Mexico, Louisiana, Alabama, Texas, and Kentucky as an agent for an unaffiliated automobile club. Club memberships entitle members to automobile breakdown and towing reimbursement and related services. The Company is paid a commission on each membership sold.
The Company offers income tax return preparation and electronic filing. This program is provided in all but a few of the Company�� the United States offices. During fiscal 2012, the Company prepared 44,000 returns. During fiscal 2012, 93.4% of the Company�� revenues were attributable to the United States customers and 6.6% were attributable to customers in Mexico. During fiscal 2012, approximately 84.7% of the Company's loans were generated through refinancings of outstanding loans and the origination of new loans to previous customers.
Advisors' Opinion:- [By Geoff Gannon]
1. World Acceptance (WRLD)
2. Express Scripts (ESRX)
3. Walgreen (WAG)
4. Humana (HUM)
5. McDonald's (MCD)Those are the kinds of companies a younger ��and poorer ��Warren Buffett might buy. Actually, a few of those companies are big enough for Warren Buffett to buy today.
- [By Canadian Value]
So I�� going to stick my next out and share my views on four battleground stocks that are among my favorite shorts: World Acceptance (WRLD), Green Mountain (GMCR), Herbalife (HLF), and InterOil (IOC). And next week at the Value Investing Congress I will present another short, my largest.
- [By Ong Kang Wei]
Besides this, I would also avoid companies which had previously fooled investors by using things such as "creative accounting" or "aggressive accounting" (Remember Enron); had been involved in a scandal which required it to restate past financials or go to court with shareholders (Remember the Diamond Foods (DMND) scam); was unable to produce financial statements on time [One recent case being World Acceptance (WRLD)]; or was being investigated by the SEC. These are all some signs of management being dishonest, and I would rather avoid companies with such a history, unless there is a change in the company's management team.
- [By Roberto Pedone]
One credit services player that insiders are jumping into big here is World Acceptance (WRLD), which is engaged in small-loan consumer finance business in the U.S. and Mexico. Insiders are buying this stock into notable weakness, since shares have dropped lower by 14.8% so far in 2014.
World Acceptance has a market cap of $734 million and an enterprise value of $1.2 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 7.5 and a forward price-to-earnings of 6.4. Its estimated growth rate for this year is 16.1%, and for next year it's pegged at 9.5%. This is not a cash-rich company, since the total cash position on its balance sheet is $14.63 million and its total debt is $559.70 million.
A director just bought 129,580 shares, or about $9.27 million worth of stock, at $71.44 to $72.08 per share.
From a technical perspective, WRLD is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock has been uptrending strong over the last few weeks, with shares moving higher from its low of $63.25 to its recent high of $75.20 a share. During that uptrend, shares of WRLD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of WRLD within range of triggering a near-term breakout trade.
If you're bullish on WRLD, then I would look for long-biased trades as long as this stock is trending above its 50-day moving average of $70.85 a share and then once it breaks out above some near-term overhead resistance at $75.20 a share with high volume. Look for a sustained move or close above that level with volume that registers near or above its three-month average volume of 169,386 shares. If that breakout materializes soon, then WRLD will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $79.54 to $84 a share.
Mu
Top 10 Income Stocks To Own Right Now: dELIA*s Inc.(DLIA)
dELiA*s, Inc. operates as a direct marketing and retail company in the United States. It offers a collection of apparel, dresses, swimwear, roomwear, footwear, outerwear, and key accessories primarily for teenage girls. The company sells its products through direct mail catalogs, Websites, and mall-based specialty retail stores under the dELiA*s brand name. As of January 29, 2011, it operated 114 dELiA*s retail stores. The company also markets and sells branded junior apparel, dresses, accessories, swimwear, footwear and outerwear primarily to young women through catalogs and Internet under the Alloy brand name. dELiA*s, Inc. was founded in 1997 and based in New York, New York.
Advisors' Opinion:- [By Sean Williams]
Don't fight history
Sometimes we just have to remember as investors that there isn't room enough for every company to succeed. Thus enters dELiA*s (NASDAQ: DLIA ) , an online and mail catalog retailer that markets apparel to teenage girls and young women.
No comments:
Post a Comment